Market Tracker

09/23 5:16pm ET

TESARO Inc (NASDAQ:TSRO)

108.59
Delayed Data
As of Sep 23
 +0.16 / +0.15%
Today’s Change
29.51
Today|||52-Week Range
110.48
+107.55%
Year-to-Date
AstraZeneca Withdraws Cediranib Marketing Application in EU
Sep 22 / Zacks.com - Paid Partner Content
Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy
Sep 20 / MotleyFool.com - Paid Partner Content
Is Tesaro Another M&A Target? The Charts Say It Is
Sep 21 / TheStreet.com - Paid Partner Content
Tesaro Gets Fast Track Designation for Ovarian Cancer Drug
Sep 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close108.43
Today’s open108.30
Day’s range107.34 - 110.48
Volume852,463
Average volume (3 months)1,199,143
Market cap$5.6B
Dividend yield--
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)-33.19%
Earnings growth (this year)-16.03%
Earnings growth (next 5 years)+21.38%
Revenue growth (last year)--
P/E ratioNM
Price/Sales6,500.72
Price/Book50.35

Competitors

 Today’s
change
Today’s
% change
UTHRUnited Therapeutics ...+0.20+0.16%
ENDPEndo International P...+3.13+15.45%
OPKOPKO Health Inc+0.23+2.12%
TAROTaro Pharmaceutical ...+0.95+0.81%
Data as of 4:02pm ET, 09/23/2016

Financials

Next reporting dateOctober 20, 2016
EPS forecast (this quarter)-$1.94
Annual revenue (last year)$317.0K
Annual profit (last year)-$251.4M
Net profit margin-79,308.52%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Leon O. Moulder
President, Chief Operating Officer &
Director
Mary Lynne Hedley
Corporate headquarters
Waltham, Massachusetts

Forecasts